Years of research have yet to produce convincing evidence that the gut microbiome plays a causal role in autism spectrum disorder (ASD), a group of scientists contended in a new opinion paper. They noted that small, methodologically weak studies — and the media attention they attracted — have helped sustain an unproven theory.

After evaluating the field’s most-cited papers, the authors concluded that claims linking gut bacteria to autism have far outpaced the data. Many studies, they noted, suffer from design flaws or exaggerated interpretations that have fueled public fascination and spurred experimental treatments such as probiotics, fecal transplants, and restrictive diets.

“Our key message is that clinicians and families should pause before pursuing microbiome-based interventions for autism,” lead author Kevin Mitchell, PhD, associate professor of genetics and neuroscience at Trinity College Dublin, Dublin, Ireland, told Medscape Medical News.

“The appeal of the microbiome hypothesis lies in the idea of an intervenable mechanism, but our assessment shows that those claims don’t hold up,” he added.

The paper was published online on November 13 in Neuron.

Popular Idea, Weak Data

The idea that gut microbes might contribute to ASD gained traction over the past decade as diagnoses increased and both scientists and families searched for explanations beyond genetics.

The “gut-brain axis” — the proposed pathway through which intestinal bacteria might influence brain function and behavior — offered a seemingly tangible biological mechanism that could be targeted with treatment.

Interest in the microbiome was also fueled by the observation that gastrointestinal problems occur more frequently in individuals with ASD than in their peers. Early studies proposed that a “leaky gut” or microbial imbalance might contribute to both digestive and behavioral symptoms, and this remains an active, though mixed, area of research.

However, the authors argued that the apparent increase in ASD diagnoses is largely explained by broader diagnostic criteria, greater awareness, and improved screening rather than a rise in prevalence.

They also suggested that gut and microbiome differences may instead result from restricted diets, sensory-based food preferences, or shared genetic factors, without implying any causal role for gut bacteria.

Mitchell and colleagues took aim at what they described as a self-reinforcing body of research linking the gut microbiome to ASD. Rather than converging on a reliable pattern, they noted that many studies have “triangulated” on inconsistent findings, each citing others as evidence of a connection that remains unproven.

Their analysis showed that across observational studies, animal experiments, and small clinical trials, results were statistically weak, inconsistent, and difficult to reproduce.

In human studies, many highly cited papers compared the gut microbiomes of individuals with and without ASD using sample sizes as small as 7-43 participants per group, when meaningful comparisons would require samples in the thousands.

A ‘Dead End?’

The researchers reported that apparent differences often failed to hold up in larger or better-controlled studies. Follow-up research using sibling controls or adjusting for diet and environmental factors showed no consistent differences in gut microbial composition between participants with and without ASD.

The authors also identified methodological problems in animal studies. In some of the most publicized experiments, gut bacteria from children with ASD were transplanted into germ-free mice, which investigators reported then showed “autistic-like behaviors.”

Mitchell and his co-authors noted that these studies used small samples, loosely defined behavioral measures, and statistical methods that overstated effects, making the results appear more robust than they were.

Clinical trials had similar limitations. Most were open-label, lacked placebo controls, and used inconsistent outcome measures. Even the few randomized or blinded studies were underpowered, and the largest clinical trial found no significant difference between fecal transplant and placebo groups.

“There’s variability in all three of those areas, and the studies just don’t form a coherent story at all,” said senior author and developmental neuropsychologist Dorothy Bishop, DPhil, of the University of Oxford in Oxford, England. “The initial impression that this literature as a whole represents a body of supportive work disintegrates when one looks at the details, with little consistency in findings from study to study.”

The authors outlined two directions for future research. One is to proceed but with far greater rigor, including clear hypotheses, adequate statistical power, standardized methods, preregistration, and replication before publication. They also urged genuine triangulation, seeking converging evidence across different methods.

The other option, they wrote, is to acknowledge that the field may have reached a “dead end” and that continued investment of time and resources may not be warranted.

Although they doubted that research would stop altogether, they said scientists who continue should first ask what kind of evidence would truly convince them that this is a productive line of inquiry.

“Our impression,” they concluded, “is that autism-microbiome research has generated its own momentum, without necessarily going anywhere.”

In Defense of the Science

Commenting on the paper, Lisa Aziz-Zadeh, PhD, a neuroscientist at the University of Southern California in Los Angeles, who studies how gut metabolites influence brain function and behavior, noted that her own research was not cited in the perspective.

She acknowledged that stronger, better-controlled studies are needed to clarify the microbiome’s role in autism but cautioned against dismissing the field altogether.

“The answer to earlier, less rigorous studies isn’t to abandon the research,” she told Medscape Medical News. “It’s to conduct future, more rigorous ones.”

She said any model of autism must include the brain as the intermediary between gut health and behavior.

“You can’t have a model of autism that excludes the brain,” she said, noting that future research should integrate microbiome, brain imaging, and behavioral data, ideally in longitudinal studies beginning during pregnancy or early infancy, when causal effects are most plausible.

Her lab has identified links between microbial tryptophan metabolites, brain activity, and autism symptoms, suggesting one pathway by which gut biochemistry may influence neural processing.

Contradictory results are common across autism research, she added, but larger collaborative studies and better controls could bring more consistency.

“In neuroscience, early MRI studies also showed inconsistent results until datasets grew and methods improved,” she said. “We should offer the same patience here.”

Also commenting on the paper, Rosa Krajmalnik-Brown, PhD, professor and director of the Center for Health Through Microbiomes at Biodesign Institute at Arizona State University in Tempe, Arizona, disputed the suggestion that the field may have reached a dead end. Her research was among the studies referenced in the critique, which she said downplayed its significance.

“They used acknowledged limitations, such as small, open-label samples, to minimize the impact of our work,” she told Medscape Medical News. “We have never claimed causation. Our studies showed improvements in gastrointestinal and some autism-related symptoms, along with changes in gut microbiota and key metabolites.”

Her team is conducting randomized, placebo-controlled trials in both adults and children with autism to address many of the methodological weaknesses cited in the perspective.

“We know firsthand from parents that in our first open-label study, we changed lives,” Krajmalnik-Brown said. “Future studies must build on what we’ve learned through larger, well-controlled trials that track both microbial and metabolic changes.”

The perspective authors reported having no funding, competing interests, or disclosures. Aziz-Zadeh reported having no relevant conflicts of interest. Her recent study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the US Department of Defense. Krajmalnik-Brown reported having pending or approved patents for autism biomarkers and the use of microbiota transfer therapy for various conditions, including autism. She is a co-founder of Autism Diagnostics LLC and Gut-Brain Axis Therapeutics.